Ozmosi | Dasatinib Drug Profile

Product Description

Dasatinib is used to treat a certain type of chronic myeloid leukemia (CML; a type of cancer of the white blood cells) as a first treatment and in people who can no longer benefit from other leukemia medications including imatinib (Gleevec) or in those who cannot take these medications because of side effects. Dasatinib is also used to treat a certain type of chronic CML in children. Dasatinib is also used to treat a certain type of acute lymphoblastic leukemia (ALL; a type of cancer of the white blood cells) in people who can no longer benefit from other leukemia medications or who cannot take these medications because of side effects. Dasatinib is in a class of medications called kinase inhibitors. It works by blocking the action of an abnormal protein that signals cancer cells to multiply. This helps stop the spread of cancer cells. (Sourced from: https://medlineplus.gov/druginfo/meds/a607063.html)

Mechanisms of Action: TK Inhibitor

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Oral

FDA Designation: *

Approval Status: Approved

Approved Indications: None

Known Adverse Events: None

Company: Bristol-Myers Squibb
Company Location: Eastern America
Company CEO: Giovanni Caforio
Additional Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Dasatinib

Countries in Clinic: Argentina, Australia, Austria, Belgium, Brazil, Bulgaria, Canada, China, Czech Republic, Denmark, Finland, France, Germany, Hungary, India, Ireland, Israel, Italy, Jordan, Korea, Lebanon, Malaysia, Netherlands, Norway, Portugal, Russia, Saudi Arabia, Singapore, Slovakia, Spain, Sweden, Switzerland, Taiwan, Tunisia, United Kingdom, United States, Vietnam

Active Clinical Trial Count: 24

Recent & Upcoming Milestones

Highest Development Phases

Phase 3: Acute Lymphoid Leukemia|Chronic Myeloid Leukemia|Precursor Cell Lymphoblastic Leukemia-Lymphoma

Trial ID	Trial	Phase	Trial Status	Disease	Primary Completion Date	Probability of Success	Latest Trial Update Date	Data Updated
NCT04603872	DASA001	P1	Recruiting	Lymphoma, Non-Hodgkin\|Acute Lymphoid Leukemia\|Leukemia, Plasma Cell\|Multiple Myeloma\|Precursor Cell Lymphoblastic Leukemia-Lymphoma	2023-11-01	59%	2020-10-28	Primary Endpoints\|Treatments
NCT05751044	HEM-iSMART B	P2	Recruiting	B-Cell Leukemia\|Precursor T-Cell Lymphoblastic Leukemia-Lymphoma\|Lymphoma, B-Cell\|T-Cell Leukemia\|Precursor Cell Lymphoblastic Leukemia-Lymphoma\|Precursor B-Cell Lymphoblastic Leukemia-Lymphoma\|Acute Lymphoid Leukemia	2032-02-01	2%	2025-09-17	Primary Completion Date\|Primary Endpoints\|Start Date\|Study Completion Date\|Treatments\|Trial Status
NCT06390319	SJALL23T	P2	Recruiting	Precursor T-Cell Lymphoblastic Leukemia-Lymphoma\|Precursor Cell Lymphoblastic Leukemia-Lymphoma\|T-Cell Peripheral Lymphoma\|Acute Lymphoid Leukemia\|T-Cell Leukemia	2027-12-01	2%	2025-02-04	Patient Enrollment\|Primary Endpoints\|Treatments
NCT05007873	NCI-2021-08486	P2	Recruiting	Myelogenous, Chronic, BCR-ABL Positive Leukemia\|Chronic Myeloid Leukemia	2026-10-30	12%	2024-08-28	Primary Completion Date\|Primary Endpoints\|Study Completion Date\|Treatments
NCT06018467	SENIOR	P2	Recruiting	Osteoporosis\|Bone Diseases, Metabolic	2025-12-31	50%	2023-10-03	Primary Endpoints\|Start Date\|Treatments
2021-001288-26	2021-001288-26	P2	Active, not recruiting	HIV Infections	2024-07-29
NCT01471106	NCI-2012-00037	P2	Completed	Breast Cancer	2024-01-31	61%	2024-07-11	Primary Completion Date\|Primary Endpoints\|Study Completion Date
NCT03117751	TOT17	P3	Active, not recruiting	Acute Lymphoid Leukemia\|Precursor Cell Lymphoblastic Leukemia-Lymphoma	2026-09-30	10%	2024-11-27	Primary Endpoints\|Treatments
NCT01254864	NCI-2011-00267	P2	Completed	Prostate Cancer	2023-12-07	47%	2023-12-16	Primary Completion Date\|Primary Endpoints\|Study Completion Date\|Treatments\|Trial Status
NCT03595917	NCT03595917	P1	Recruiting	Chronic Lymphoid Leukemia\|Acute Myeloid Leukemia\|Burkitt Lymphoma\|B-Cell Leukemia\|Lymphoma, B-Cell\|Blast Crisis\|Chronic Myeloid Leukemia\|Acute Lymphoid Leukemia\|Myelogenous, Chronic, BCR-ABL Positive Leukemia	2026-11-01	12%	2025-11-05	Primary Completion Date\|Primary Endpoints\|Study Completion Date\|Treatments
NCT05993949	IRB-68603	P1	Active, not recruiting	Lymphoid Leukemia\|Precursor Cell Lymphoblastic Leukemia-Lymphoma	2027-06-01	12%	2025-09-24	Patient Enrollment\|Primary Completion Date\|Primary Endpoints\|Study Completion Date\|Treatments\|Trial Status
jRCT2021210060	jRCT2021210060	P3	Active, not recruiting	Chronic Myeloid Leukemia	2029-03-31
NCT03020030	NCT03020030	P3	Active, not recruiting	Precursor Cell Lymphoblastic Leukemia-Lymphoma\|Acute Lymphoid Leukemia	2026-11-30	50%	2025-01-04
2015-003502-16	DasaHIT	P3	Completed	Chronic Myeloid Leukemia	2023-03-31		2025-07-04	Treatments
NCT04872790	STUDY00022691	P1	Recruiting	Precursor Cell Lymphoblastic Leukemia-Lymphoma\|Acute Lymphoid Leukemia	2026-12-31	12%	2025-03-07	Primary Completion Date\|Primary Endpoints\|Treatments
NCT06145217	XS004-17	P1	Completed	Healthy Volunteers	2023-08-22		2023-11-27	Primary Endpoints\|Treatments
NCT06257394	VHR ALL	P2	Recruiting	Acute Lymphoid Leukemia\|Precursor Cell Lymphoblastic Leukemia-Lymphoma	2034-12-31		2025-06-10	Primary Completion Date\|Primary Endpoints\|Start Date\|Study Completion Date\|Treatments\|Trial Status
NCT06533748	SJALL23H	P2	Recruiting	Acute Lymphoid Leukemia\|Precursor Cell Lymphoblastic Leukemia-Lymphoma	2028-05-01	2%	2025-01-11
2010-019119-39	GIMEMA Study LAL1509	P2	Completed	Acute Lymphoid Leukemia	2024-12-31		2025-05-06	Primary Completion Date\|Study Completion Date\|Treatments\|Trial Status
2024-510784-36-00	CA180-226	P2	Completed	Chronic Myeloid Leukemia	2024-10-25		2025-05-02	Treatments
NCT03625388	LPI-JOR-LEB-KSA-TUN-2017-01	P2	Completed	Chronic Myeloid Leukemia\|Myelogenous, Chronic, BCR-ABL Positive Leukemia	2023-07-22	55%	2023-09-23	Patient Enrollment\|Primary Completion Date\|Primary Endpoints\|Study Completion Date\|Treatments\|Trial Status
2016-004106-34	2016-004106-34	P2	Completed	Chronic Myeloid Leukemia	2023-02-01		2025-07-05	Treatments
CTR20132365	CTR20132365	P2	Recruiting	Acute Lymphoid Leukemia\|Acute Myeloid Leukemia\|Chronic Lymphoid Leukemia\|Chronic Myeloid Leukemia	None		2025-04-29	Patient Enrollment\|Treatments
CTR20131053	CTR20131053	P2	Active, not recruiting	Leukemia	None		2025-04-29	Treatments

Recent News Events

Date	Type	Title
01/09/2026	News Article	ACTG Launches IPACE-HIV to Study Frailty Intervention
01/07/2026	News Article	Terns Pharmaceuticals to Highlight 2026 Priorities and Program Milestones at the 44th Annual J.P. Morgan Healthcare Conference
12/05/2025	News Article	K36 Therapeutics announces presentation of First-in-Human Clinical Data for Gintemetostat (KTX-1001) Demonstrating Target Engagement and Clinical Activity in Multiple Myeloma at ASH 2025 and the Appointment of Dr. Shinta Cheng, M.D., Ph.D., as Chief Medical Officer
11/03/2025	News Article	Enliven Therapeutics Announces Clinical Data in CML Patients with Atypical Fusion Transcripts at ASH 2025 Annual Meeting

Did PRYZM just deliver the data you were looking for?
Did you try our Excel download too?

Now that you've used PRYZM, we hope you're able to see for yourself that it was designed and developed by people who actually use this data for a living. By applying next-generation technology for aggregating and curating this info across multiple key sources PRYZM delivering the latest information at your fingertips just the way you need it and with industry leading speed and cost effectiveness.

Our subscribers enjoy unlimited searches and receive this data on their own secure instance so they can overlay any additional internal/proprietary data on top of the search results and blend that data with real-time industry intel from PRYZM. Discover how you can continue to uncover the competitive landscape and drive strategy.

Suggestions

Session Expiring Soon

Dasatinib

Alternative Names: dasatinib, sprycel, bms-354825, DAZATINIB Clinical Status: Inactive Latest Update: 2026-01-15 Latest Update Note: Clinical Trial Update